findmyKOL
Clinical trialNCT04334759CompletedPhase 3Interventional

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

SponsorPrECOG, LLC.Enrollment214Malignant Pleural MesotheliomaMesotheliomaPleural Mesothelioma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Patients with pleural mesothelioma (PM) that cannot be surgically removed will receive standard chemotherapy (cisplatin or carboplatin and pemetrexed) given with durvalumab, a type of immunotherapy, or a treatment chosen by the study doctor, which is either standard chemotherapy or immunotherapy combination (ipilimumab and nivolumab). Durvalumab is an antibody (a type of human protein) that works by blocking a body substance called Programmed Death-Ligand 1 (PD-L1). Blocking PD-L1 helps the body's immune system attack cancer cells. Research has shown that durvalumab can slow tumor growth and shrink tumors in some people with cancer. Previous studies of combining durvalumab and chemotherapy showed that this combination is active in advanced mesothelioma. The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with PM.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

57 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • Canberra Hospital

    Garran, Australian Capital Territory, Australia

  • Blacktown Hospital

    Blacktown, New South Wales, Australia

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia

  • Coffs Harbour Health Campus

    Coffs Harbour, New South Wales, Australia

  • Gosford Hospital

    Gosford, New South Wales, Australia

  • Wyong Hospital

    Hamlyn Terrace, New South Wales, Australia

  • Nepean Hospital

    Kingswood, New South Wales, Australia

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • Orange Health Service

    Orange, New South Wales, Australia

  • Northern Cancer Institute (genesiscare)

    Saint Leonards, New South Wales, Australia

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Icon Cancer Care Wesley

    Auchenflower, Queensland, Australia

  • Sunshine Coast University Hospital

    Birtinya, Queensland, Australia

  • Icon Cancer Care Chermside

    Chermside, Queensland, Australia

  • the Prince Charles Hospital

    Chermside, Queensland, Australia

  • Townsville University Hospital

    Douglas, Queensland, Australia

  • Icon Cancer Care South Brisbane

    South Brisbane, Queensland, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia

  • the Queen Elizabeth Hospital

    Woodville South, South Australia, Australia

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia

  • Launceston General Hospital

    Launceston, Tasmania, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • Peninsula & South Eastern Haematology and Oncology Group

    Frankston, Victoria, Australia

  • Austin Hospital

    Heidelberg, Victoria, Australia

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia

  • Epworth Healthcare - Richmond

    Richmond, Victoria, Australia

  • Sunshine Hospital (western Health)

    Saint Albans, Victoria, Australia

  • Goulburn Valley Health

    Shepparton, Victoria, Australia

  • Sir Charles Gairdner Hospital (scgh)

    Nedlands, Western Australia, Australia

New Zealand
  • Auckland City Hospital

    Grafton, Auckland, New Zealand

United States
  • University of California San Diego

    La Jolla, California, United States

  • University of Miami

    Miami, Florida, United States

  • Moffitt Cancer Center

    Tampa, Florida, United States

  • Emory University

    Atlanta, Georgia, United States

  • University of Chicago

    Chicago, Illinois, United States

  • Northshore University Health System/kellogg Cancer Center

    Evanston, Illinois, United States

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

17 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Durvalumab →Ipilimumab and NivolumabStandard Chemotherapy
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
18 Feb 2021
Primary completion
20 Jun 2025
Completion
30 Jun 2025
Last update posted
22 Jan 2026
Registered enrollment
214
Registry id
NCT04334759
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.